From the ‘scurfy’ mouse to the Nobel Prize: How a Seattle biotech pioneer’s long game paid off
Seattle scientist Fred Ramsdell’s decades-long research into regulatory T cells culminated in a Nobel Prize and continues to shape new cell therapies.
Ramsdell’s work began at Darwin Molecular, where a mission-driven approach enabled foundational discoveries around the Foxp3 gene and immune system regulation using the “scurfy” mouse model. “People bought into that because you’re trying to do something that would make a difference,” he said, reflecting on a research culture not driven by rapid commercialization. His work ultimately revealed how regulatory T cells can be used to treat autoimmune disease and improve cancer immunotherapy, and now informs ongoing efforts at Sonoma Biotherapeutics and the Parker Institute for Cancer Immunotherapy.
This trajectory highlights the region’s strength in long-term scientific investment and its ability to translate foundational discoveries into next-generation therapeutics.